We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+0.64%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.26B
AUM Growth
-$618M
(-11%)
Cap. Flow
-$615M
Cap. Flow
% of AUM
-11.69%
Top 10 Holdings %
Top 10 Hldgs %
13.58%
Holding
928
New
151
Increased
197
Reduced
368
Closed
132
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$43.8M |
| 2 |
UnitedHealth
UNH
|
+$42.1M |
| 3 |
Verizon
VZ
|
+$32.3M |
| 4 |
Comcast
CMCSA
|
+$29.1M |
| 5 |
Citigroup
C
|
+$23.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$70.8M |
| 2 |
Apple
AAPL
|
+$38.4M |
| 3 |
Johnson & Johnson
JNJ
|
+$36.3M |
| 4 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$31.3M |
| 5 |
International Flavors & Fragrances
IFF
|
+$28.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 17.72% |
| 2 | Healthcare | 17.4% |
| 3 | Technology | 16.88% |
| 4 | Industrials | 10.63% |
| 5 | Consumer Discretionary | 10.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$4.72T
| $182M | 3.46% |
5,799,560
-1,201,988
| -17% | -$38.4M |
|
2
Gilead Sciences
GILD
$162B
| $73.7M | 1.4% |
629,833
-110,267
| -15% | -$12M |
|
3
Walt Disney
DIS
$161B
| $64.7M | 1.23% |
567,050
-111,630
| -16% | -$12.3M |
|
4
Amgen
AMGN
$199B
| $59.3M | 1.13% |
386,390
-84,827
| -18% | -$13.6M |
|
|
5
Verizon
VZ
$186B
| $57.9M | 1.1% |
1,242,425
+659,320
| +113% | +$32.3M |
|
|
6
Comcast
CMCSA
$82.2B
| $57.5M | 1.09% |
1,912,360
+990,700
| +107% | +$29.1M |
|
7
ExxonMobil
XOM
$653B
| $56.6M | 1.08% |
680,389
-89,190
| -12% | -$7.67M |
|
8
Electronic Arts
EA
$52.4B
| $55.1M | 1.05% |
827,858
-164,830
| -17% | -$10.1M |
|
9
Merck
MRK
$323B
| $54M | 1.03% |
993,557
-157,482
| -14% | -$8.83M |
|
10
Amazon
AMZN
$2.5T
| $53.4M | 1.02% |
2,462,220
-988,960
| -29% | -$20.7M |
|
11
Boeing
BA
$165B
| $52M | 0.99% |
374,780
+6,017
| +2% | +$878K |
|
12
Visa
V
$665B
| $51.6M | 0.98% |
769,102
-104,090
| -12% | -$7.05M |
|
13
Pfizer
PFE
$143B
| $51.3M | 0.98% |
1,611,687
-6,082
| -0.4% | -$198K |
|
14
Mastercard
MA
$465B
| $50.8M | 0.97% |
543,226
-76,770
| -12% | -$7.04M |
|
15
Intel
INTC
$511B
| $50.7M | 0.96% |
1,666,029
-182,300
| -10% | -$5.89M |
|
|
CELG
16
DELISTED
Celgene Corp
CELG
| $50.4M | 0.96% |
435,651
-70,050
| -14% | -$8.01M |
|
17
Kroger
KR
$34.2B
| $49M | 0.93% |
1,352,480
-262,860
| -16% | -$9.56M |
|
18
AbbVie
ABBV
$454B
| $44.8M | 0.85% |
667,424
-344,926
| -34% | -$22.5M |
|
|
19
Bristol-Myers Squibb
BMY
$126B
| $44.5M | 0.85% |
668,358
+664,158
| +15,813% | +$43.8M |
|
20
Union Pacific
UNP
$184B
| $44.1M | 0.84% |
462,829
-77,970
| -14% | -$8.13M |
|
21
McKesson
MCK
$95.9B
| $43.9M | 0.83% |
195,135
-32,334
| -14% | -$7.48M |
|
|
22
UnitedHealth
UNH
$384B
| $43.4M | 0.83% |
+355,991
| New | +$42.1M |
|
23
DuPont de Nemours
DD
$18.6B
| $40.9M | 0.78% |
315,388
-47,539
| -13% | -$6.16M |
|
|
24
Johnson & Johnson
JNJ
$621B
| $40.6M | 0.77% |
416,230
-362,220
| -47% | -$36.3M |
|
25
Cardinal Health
CAH
$52.5B
| $40.4M | 0.77% |
482,604
-41,350
| -8% | -$3.65M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2015 Portfolio in Review
As of Q2 2015, Jacobs Levy Equity Management held 928 positions worth $5.26B, down 11% from $5.88B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jacobs Levy Equity Management withdrew a net $615M in Q2 2015, closing 132 positions and reducing 368 holdings. Its most notable exit was BROADCOM CORP CL-A, an estimated $31.3M position sold in full.
By sector, the portfolio is most concentrated in Financials at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Jacobs Levy Equity Management opened a new position in UnitedHealth worth $43.4M.
- Jacobs Levy Equity Management's largest Q2 2015 buy was UnitedHealth: 355,991 shares worth $43.4M.
- Jacobs Levy Equity Management added most to Bristol-Myers Squibb in Q2 2015, an estimated $43.8M increase.
- Jacobs Levy Equity Management's biggest Q2 2015 reduction was Microsoft, cutting an estimated $70.8M.
- Jacobs Levy Equity Management fully exited BROADCOM CORP CL-A in Q2 2015, selling an estimated $31.3M.
- Jacobs Levy Equity Management's ten largest holdings make up 14% of its $5.26B portfolio in Q2 2015.
- Jacobs Levy Equity Management opened 151 new positions and closed 132 in Q2 2015.
- Jacobs Levy Equity Management's portfolio value fell 11% quarter-over-quarter to $5.26B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2015, filed 14 Aug 2015.